Epiva

About Epiva

Epiva Biosciences was a biotechnology firm established in 2014, originating from the VentureLabs innovation foundry of Flagship Ventures. The company focused on the development of immunobiotic therapeutics aimed at treating a range of conditions including autoimmune diseases, inflammation, and cancer. Its core scientific premise was the modulation of the host immune-bacteria interface to restore a healthy microbiome, a state referred to as normo-biosis.

The company's primary business was in the biotechnology and drug discovery sectors, operating within the life sciences market. Its client base would have consisted of partners in the pharmaceutical industry and eventually patients, upon successful clinical trials and regulatory approval. The business model was centered on research and development, funded by venture capital, with the goal of bringing novel therapeutics to market. In January 2015, the company secured $6.06 million in a Series A funding round.

In a strategic move to consolidate synergistic research efforts, Epiva Biosciences merged with a fellow Flagship Ventures company, Evelo Biosciences, in July 2016. Both companies were pursuing therapies based on the microbiome. The combined entity continued under the Evelo Biosciences name, creating a more robust platform focused on the immuno-microbiome. At the time of the merger, the combined company had a team of 42 employees and approximately $40 million in financing. This merger marked the conclusion of Epiva Biosciences as an independent entity, with its assets and research programs integrated into Evelo Biosciences.